Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
24.7M
-
Shares change
-
-3.19M
-
Total reported value, excl. options
-
$205M
-
Value change
-
-$24.7M
-
Put/Call ratio
-
1.99
-
Number of buys
-
38
-
Number of sells
-
-51
-
Price
-
$8.32
Significant Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q1 2021
124 filings reported holding AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share as of Q1 2021.
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.7M shares
of 27.8M outstanding shares and own 88.68% of the company stock.
Largest 10 shareholders include ORACLE INVESTMENT MANAGEMENT INC (3.78M shares), BlackRock Inc. (2.37M shares), Birchview Capital, LP (2.21M shares), AXA S.A. (1.63M shares), VANGUARD GROUP INC (1.61M shares), Chicago Capital, LLC (1.59M shares), GRIFFIN ASSET MANAGEMENT, INC. (1.36M shares), CANNELL PETER B & CO INC (1.1M shares), Baird Financial Group, Inc. (985K shares), and BLAIR WILLIAM & CO/IL (854K shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.